The genetic testing industry is still in its infancy, but this leader is comfortably profitable and growing at a healthy clip.
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Mr. Market wields a sledgehammer and takes no prisoners. He may be right about today's move.
This is a case study of when a successful phase 3 trial isn't successful enough.
Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.
Whether it's imminent or not, it's always a good idea to be prepared.
The state legislature isn't properly valuing the power source's role in combating climate change. Will Exelon's tried-and-true strategy force a last-minute deal?
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
An SEC filing shows an activist investor is building a sizable position in the company.
The company's promising immunotherapy approach delivered impressive data in multiple studies.
The lab equipment and services provider reduced full-year fiscal 2019 revenue guidance. Is today's tumble just a big overreaction?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
Management has a plan to make the company one of the lowest-cost producers in the industry. Will it work?
The FDA has given the company's lead drug platform a potential leg up in development.
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
Don't let a historically expensive stock market get you down. Give these three bargain stocks a look.
Forty-four states have brought a lawsuit against the industry.
The water utility announced a solid Q1 performance and reiterated full-year guidance, but the real excitement lies in the pending merger with Peoples.
The all-important Cobre Panama project remains on track, but it had nothing to do with a strong start to 2019.
The lithium segment struggled to overcome weather events in Chile, but the company's more mature businesses helped to partially offset the headwind.